Guaifenesin
| Clinical data | |
|---|---|
| Pronunciation | /ɡwaɪˈfɛnɪsɪn/ gwy-FEH-nih-seen |
| Trade names | Mucinex, others |
| Other names | Glyceryl guaiacolate |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682494 |
| License data |
|
| Routes of administration | By mouth |
| Drug class | Expectorant |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | Kidney |
| Elimination half-life | 1–5 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.002.021 |
| Chemical and physical data | |
| Formula | C10H14O4 |
| Molar mass | 198.218 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| (verify) | |
Guaifenesin, also known as glyceryl guaiacolate, sold under the brand name Mucinex, among others, is an expectorant medication taken by mouth and marketed as an aid to eliminate sputum from the respiratory tract. Chemically, it is an ether of guaiacol and glycerine. It may be used in combination with other medications. A 2014 study found that guaifenesin does not affect sputum volume in upper respiratory infections (the upper respiratory system includes most breathing parts above the lungs). It has been alleged to work in 2023 by making airway secretions more liquid.
Side effects may include dizziness, sleepiness, skin rash, and nausea. While it has not been properly studied in pregnancy, it appears to be safe.
Guaifenesin has been used medically since at least 1933. It is available as a generic medication and over-the-counter (OTC). In 2022, it was the 295th most commonly prescribed medication in the United States, with more than 400,000 prescriptions. In 2022, the combination dextromethorphan/guaifenesin was the 290th most commonly prescribed medication in the United States, with more than 400,000 prescriptions.